CD8A and neoplasm: From a mechanistic perspective, ICIs mostly operate by (re)activating tumor-targeting immune responses as mediated by CD8+ cytotoxic T lymphocytes and (at least in a fraction of malignancies) natural killer (NK) and γδ T cells [192–194].